First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours

Clinical trial NCT05495295 · RECRUITING

Trial details

NCT number: NCT05495295
Sponsor: Phost'In Therapeutics
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Malignant Tumor Advanced Solid Tumor Glioblastoma Multiforme Metastatic Cancer

Start date: 2022-07-18
Primary completion: 2024-11-04
Enrollment: 149

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.